- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03673423
Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer (OBTCPAN)
Interobserver Variability In The Assessment Of Vascular Invasion In Pancreatic Cancer
Assess the degree of vascular involvement is crucial in the diagnostic and therapeutic work-up of pancreatic cancer. NCCN resectability classification is used to stratify patients (in resectable, borderline resectable and non resectable) and is based on contrast-enhanced CT scan images. Unfortunately evaluation of imaging tests may rely on some degree of subjective interpretation by observers implying a fundamental variation in patient's treatments and an irreproducibility of different center study results.
This is a multicenter diagnostic study on interobserver agreement on the resectability of pancreatic cancer based upon NCCN criteria.
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).
One hundred and thirty eight consecutive patients, able to produce an informed consent, from 18 years of age, with a non-metastatic pancreatic adenocarcinoma assessed by a contrast-enhanced high-quality CT scan will be enrolled.
69 CT scan studies provided by the centers involved (High volume for pancreatic surgery) will be randomly selected from a pool of 138 of the patients that meet the inclusion criteria. Each study will be independently reviewed by a senior radiologist and a senior surgeon of each center, blinded to patient's clinical history and CT scan report, using NCCN definition of respectability status. A CFR will be filled during the review and send to the study coordinator. The data will be than centrally analyzed to asses interobserver agreement The enrolment phase will last 6 months and the whole study will last 8 months.
Study Overview
Status
Conditions
Detailed Description
Pancreatic adenocarcinoma frequently invades peripancreatic major vessels (common hepatic artery, celiac axis, superior mesenteric artery and mesenteric-portal confluence), requiring vascular resection or precluding the possibility of a radical resection. To Asses local resectability in pancreatic cancer patients is a key step to the whole process of care and it can change dramatically the outcomes. It is also extremely important in the reproducibility of different scientific studies that stratified or included patients on this feature. Resectability status classification of pancreatic adenocarcinoma, according to the definition of the National Comprehensive Cancer Network (NCCN) is widely used in current surgical and oncological practice to define the degree of vascular invasion: this classification describes three different classes of tumor depending on the local extension and vascular involvement. Resectable cancers are defined when no contact with the main vessels can be detected, whereas borderline resectable and non resectable tumors have a different extent of vascular infiltration. The recommended staging exam to define vascular involvement of pancreatic adenocarcinoma is contrast-enhanced CT scan; NCCN recommends that all patients with suspicion of pancreatic adenocarcinoma have a dedicated pancreas protocol CT scan as part of the initial assessment. From the attribution of a patient to a resectability class (resectable, borderline resectable or non resectable) derives the choice of a specific therapeutic pathway, as suggested by NCCN guidelines. International validated criteria to define local respectability are available but they can be prone to subjective interpretation. An evaluation of interobserver agreement on local resectability for pancreatic cancer in a multicenter setting is needed to understand the reliability and reproducibility of this system.
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).One senior radiologist and one senior surgeon from different Italian high-volume Institutions will separately assess the degree of vascular invasion by pancreatic cancer and the definition of resectability status according to NCCN. 69 CT scans, randomly selected from a pool of 138 studies (provided by each center and collected by the study coordinator) of non-metastatic consecutive patients with pancreatic cancers that signed the informed consent, will be evaluated. CT scans will be provided by participating centres, that will send them to the coordinating centre until reaching the planned enrolment. The images and related DVDs will be made anonymous and identified just by serial number and initials of the patient. The CT scan reports will be collected by each centre and made available by the coordinating centre for subsequent analysis. The criteria used to define the resectability status are those developed by the NCCN and included in the latest guidelines. Observers will be blinded to the CT-scan reports, as well as to the clinical history of the patient, and to the votes of the other raters. The degree of each vessel invasion and assignment of each tumor to a category of resectability status (resectable - borderline resectable - non resectable) will be defined separately by all raters, by fulfilling a template adopted and reported in NCCN guidelines. An interrater reliability analysis using the Kappa statistic will be performed to determine consistency among observers on the respectability status. The consistency among observer will be also evaluated for each point of the criteria and section of the template to asses vascular involvement in detail.
In case of significant fair or poor agreement (K < 0.50), the participating raters (consensus group), including the study coordinator, will meet to discuss the cases that will have less than 100% agreement among all the raters. Scans will be reviewed, an open discussion ensued. Based on the discussion, the consensus group will develop proposals to address the specific areas of disagreement. The CT scans not select for the first evaluation will be than evaluated, using the proposal of the consensus group by a new set of rater (one senior radiologist and one senior surgeon from each institution involved) and the new Kappa statistic will be calculated.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Fabio Giannone, MD
- Phone Number: +3903401036108
- Email: giannone.fabio@hsr.it
Study Locations
-
-
-
Milano, Italy, 20132
- Recruiting
- Ospedale San Raffaele
-
Contact:
- Gianpaolo Balzano
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age > 18 years
- Non-metastatic pancreatic adenocarcinoma
- Availability of contrast enhanced CT scan with adequate quality. Section thickness must be <3 mm, according to NCCN recommendations
- Pathological confirmation of pancreatic adenocarcinoma by cytology/histology is not required at the time of enrolment, but it is needed before including the CT scan in the pool of exams to be evaluated.
- Signed informed consent
Exclusion Criteria:
- Evidence of metastatic disease
- Inadequate quality CT scan (non-respecting the NCCN recommendations)
- Absence of cytology/histology confirmation
- Refusal to participate in the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of interobserver variability to define vascular invasion and resectability status on CT scans
Time Frame: Eight months
|
The primary aim of the study will be the assessment of interobserver variability to define vascular invasion and resectability status on CT scans (according to the last version of the NCCN Classification).
|
Eight months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of disagreement causes and proposal of a new classification system
Time Frame: One year
|
In case of significant low agreement (K < 0,5), causes of disagreement will be assessed and a new classification of vascular involvement will be proposed to reduce the disagreement.
The new classification will be validated on the remaining 69 CT scans
|
One year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gianpaolo Balzano, MD, Ospedale San Raffaele
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- OBTCPAN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Adenocarcinoma
-
Fudan UniversityUnknownStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Xian-Jun YuCompletedStage IA Pancreatic Adenocarcinoma | Stage IB Pancreatic Adenocarcinoma | Stage IIA Pancreatic Adenocarcinoma | Stage IIB Pancreatic AdenocarcinomaChina
-
Scandion Oncology A/SAlcedis GmbHRecruitingMetastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Inoperable Disease | Localized Pancreatic AdenocarcinomaDenmark, Germany
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
Jean-Luc Van LaethemCelgene CorporationCompletedPancreatic Adenocarcinoma Resectable | Pancreatic Adenocarcinoma Metastatic | Pancreatic Adenocarcinoma Locally AdvancedBelgium